Por que não colher citologia antes dos 25 anos?

O Câncer do colo do útero, apesar de prevenível e tratável, ainda é o responsável pela morte de cerca de 5 mil mulheres por ano no Brasil. A realização do exame colpocitológico é ação importante do rastreamento adequado em mulheres entre 25 e 64 anos.

Download da apresentação em: <https://www.arca.fiocruz.br/handle/icict/58268>

Conteúdo Relacionado

• Postagem – Rastreamento do câncer do colo do útero: cobertura, periodicidade e população-alvo
• Postagem – Rastreamento do câncer do colo do útero: adequabilidade da amostra
• Postagem – Principais questões sobre Rastreio do Câncer de Colo de Útero
• Postagem – Exames Preventivos na Mulher: indo além do Rastreio dos Cânceres de Colo e de Mama

Referências citadas

• Diretrizes brasileiras para o rastreamento do câncer do colo do útero
  Instituto Nacional de Câncer José Alencar Gomes da Silva. Coordenação de Prevenção e Vigilância. Divisão de Detecção Precoce e Apoio à Organização de Rede. Diretrizes brasileiras para o rastreamento do câncer do colo do útero / Instituto Nacional de Câncer José Alencar Gomes da Silva. Coordenação de Prevenção e Vigilância. Divisão de Detecção Precoce e Apoio à Organização de Rede. – 2. ed. rev. atual. – Rio de Janeiro: INCA, 2016.
• Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies
  INTERNATIONAL AGENCY OF RESEARCH ON CANCER. IARC Working Group on Evaluation of Cervical Cancer Screening Programmes. Screening for squamous cervical cancer: duration of low risk after negative results of cervical cytology and its implication for screening policies. British Medical Journal, v.293, n. 6548, p. 659-664, 1986.
• Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data
  SASIENI, P.; CASTAÑON, A.; CUZICK, J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. British Medical Journal, v. 339, n. 2968, 2009.
• Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years
  Landy R, Birke H, Castanon A, Sasieni P. Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years. Br J Cancer. 2014 Apr 2;110(7):1841-6. doi: 10.1038/bjc.2014.65. Epub 2014 Feb 11. PubMed PMID: 24518600; PubMed Central PMCID: PMC3974083.
• The association between cervical cancer screening and mortality from cervical cancer: a population based case-control study
  Vicus D, Sutradhar R, Lu Y, Elit L, Kupets R, Paszat L; Investigators of the Ontario Cancer Screening Research Network. The association between cervical cancer screening and mortality from cervical cancer: a population based case-control study. Gynecol Oncol. 2014 May;133(2):167-71. doi: 10.1016/j.ygyno.2014.02.037. Epub 2014 Feb 28. PubMed PMID: 24589414.
• High-grade squamous intraepithelial lesion in women aged <30 years has a prevalence pattern resembling low-grade squamous intraepithelial lesion
  Vale DB, Westin MC, Zeferino LC. High-grade squamous intraepithelial lesion in women aged <30 years has a prevalence pattern resembling low-grade squamous intraepithelial lesion. Cancer Cytopathol. 2013 Oct;121(10):576-81. doi: 10.1002/cncy.21312. Epub 2013 Jun 13. PubMed PMID: 23765869.
• Prognosis of intraepithelial cervical lesion during adolescence in up to two years of follow-up
  MONTEIRO, D. L. et al. Prognosis of intraepithelial cervical lesion during adolescence in up to two years of follow-up. Journal of Pediatric and Adolescent Gynecology, v. 23, n. 4, p. 230-236, 2010.
• Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease
  Kyrgiou M, Athanasiou A, Kalliala IEJ, Paraskevaidi M, Mitra A, Martin-Hirsch PP, Arbyn M, Bennett P, Paraskevaidis E. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database Syst Rev. 2017 Nov 2;11:CD012847. doi: 10.1002/14651858.CD012847. Review. PubMed PMID: 29095502; PubMed Central PMCID: PMC6486192.